De-escalation protocols — tapering GLP-1 dose for maintenance

Dr.ObesityLA said:

The trials generally allowed a step to be held or reduced and then retried, and people who did that mostly arrived at the same place a few weeks…

PSA for titration users considering the 0.25mg starting dose: this dose is NOT intended for weight loss. It's a titration dose to let your body adjust. Don't be discouraged if you don't lose much in the first month.

The therapeutic dose for weight management starts at 1.7mg (semaglutide) or 5mg (tirzepatide). Be patient with the ramp-up.

Following on from Dr.PainCLE — and this may be the naive question:

Why the interval is four weeks rather than two, and whether a slower ladder gets to the same place?

FDA_TrackerJim said:

PSA for titration users considering the 0.25mg starting dose: this dose is NOT intended for weight loss.

Adding the part of the answer the thread has not reached. Extending the interval and reducing the dose are pharmacologically different. Reducing the dose lowers the whole exposure curve evenly; extending the interval keeps the peak and drops the trough. Since the appetite effect tracks the trough, interval extension tends to give you good days and bad days rather than a uniformly smaller effect, which most people find harder to live with.

If somebody has the primary source to hand I would rather cite it than paraphrase it.

Reporting back.

I held the step an extra three weeks instead of stepping back down, and it settled. Same dose, same everything, just more time — which is exactly what was suggested upthread.

rachel_ABQ said:

Extending the interval and reducing the dose are pharmacologically different.

That is right for the weekly injectables. For the daily agents the interval logic is different and the four-week convention does not transfer.

Worth separating that from the maintenance and discontinuation question, which this thread keeps folding into the same question. They behave differently and the advice does not transfer.